ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 571,57
0,91%
Dow Jones
38 792,48
0,53%
DAX
18 068,21
0,26%
Brent Oil
83,48
1,65%
Bitcoin
66 678,37
0,06%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Pardes Biosciences Inc (PRDS)

  7. Pardes Biosciences Inc (PRDS) Actualités

PRDS

Pardes Biosciences (PRDS)

Pardes Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PRDS
DateHeureSourceTitreSymboleSociété
11/09/202314h00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:PRDSPardes Biosciences Inc
31/08/202323h17Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202320h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRDSPardes Biosciences Inc
31/08/202315h06Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PRDSPardes Biosciences Inc
31/08/202315h03Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PRDSPardes Biosciences Inc
31/08/202314h59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRDSPardes Biosciences Inc
31/08/202314h53Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202314h34Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202314h30Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:PRDSPardes Biosciences Inc
31/08/202314h15GlobeNewswire Inc.Pardes Biosciences Announces Closing of Tender OfferNASDAQ:PRDSPardes Biosciences Inc
28/08/202317h33Business WireMediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesNASDAQ:PRDSPardes Biosciences Inc
17/08/202323h43Business WireMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesNASDAQ:PRDSPardes Biosciences Inc
04/08/202322h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRDSPardes Biosciences Inc
28/07/202323h08Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:PRDSPardes Biosciences Inc
28/07/202323h04Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:PRDSPardes Biosciences Inc
28/07/202323h01Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:PRDSPardes Biosciences Inc
17/07/202313h58Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:PRDSPardes Biosciences Inc
17/07/202313h11Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:PRDSPardes Biosciences Inc
17/07/202313h00GlobeNewswire Inc.Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsNASDAQ:PRDSPardes Biosciences Inc
05/06/202322h03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PRDSPardes Biosciences Inc
02/06/202322h14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PRDSPardes Biosciences Inc
05/05/202322h06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PRDSPardes Biosciences Inc
05/05/202322h01GlobeNewswire Inc.Pardes Biosciences Reports First Quarter 2023 Financial ResultsNASDAQ:PRDSPardes Biosciences Inc
21/04/202322h28Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PRDSPardes Biosciences Inc
20/04/202313h54Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PRDSPardes Biosciences Inc
20/04/202313h50Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PRDSPardes Biosciences Inc
03/04/202314h00GlobeNewswire Inc.Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19NASDAQ:PRDSPardes Biosciences Inc
14/03/202321h07Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PRDSPardes Biosciences Inc
14/03/202321h01GlobeNewswire Inc.Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:PRDSPardes Biosciences Inc
14/02/202323h07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PRDSPardes Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:PRDS

Dernières Valeurs Consultées

LSE
HIJP
H Msci Jpis Esg
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés